Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report

Baby S;Khalil F;Tanvetyanon T;;
cancer treatment and research communications 2021 Vol. 28 pp. -
157
s2021cancerfrontline

Abstract

RET-rearrangement occurs in 1 to 2% of patients with non-small cell lung cancer (NSCLC), typically among non-smokers, and it is associated with an increased incidence of brain metastasis. While selpercatinib and pralsetinib are active for RET-rearranged NSCLC, the optimal standard frontline regimen …

Keywords

National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34166867 doi:10.1016/j.ctarc.2021.100423 sheon baby farah khalil tawee tanvetyanon

Access

URL:
http://www.ncbi.nlm.nih.gov/pubmed/34166867

Citation

ID: 271639
Ref Key: s2021cancerfrontline
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
271639
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store